

# Minute Report on the Meeting of the Technical Working Group (TWG) on HIV Care and Treatment and Clinical Mentor Team Members

Date: 16/05/2025

Time:9-12 AM

Location: NCHADS meeting room A

Attendees: [List of attendees]

## Objective:

- Reviewing the AHD and NCD Survey: refining research conclusions, and results.
- Update on new guidelines of ART treatment.
- Discussing the appropriate use of Tenofovir Alafenamide (TAF).

## Key Discussions:

### 1. AHD and NCD Survey Presentation

- Presented by the Research Unit,
  - Still not approve from the integration SOP of Non-Communicable Diseases (NCD) and Anti-Retroviral Therapy (ART).
  - The US-CDC had been involved in this survey.
  - The following specific points were raised:
    - Clarification on whether TPT completion was applicable among People Living with HIV (PLHIV).
    - Concerns were raised regarding hypertension screening (total of 297, with 22 cases identified).
    - Limitations of the survey were discussed, emphasizing the need to list all relevant points.
    - Recommendations should be strictly based on the findings presented and not extend beyond the topic.
    - After the meeting, a small group will make an appointment to review the data analysis again.



- Further Inquiries:

- Dr. Sarongkea inquired about the availability of CD4 tests for documentation and proposed investigating TPT treatment outcomes if feasible. Concerns about the underutilization of Expert MTB/RIF were also highlighted.
- Dr. Narom raised points regarding the interpretation of CD4 counts.
- Dr. Sovannarith stressed the importance of TPT percentages and the high rate of AHD, advocating for increased testing and screening measures.
- Dr. Setha reinforced the necessity of screenings, maintaining their relevance regardless of treatment advancements.
- While acknowledging the small sample size in comparison to the total number of PLHIV, the group agreed that CD4 testing should be routine.
- Dr. Vanthy pointed out the lack of completeness in patient charts, and emphasizing case management across all sites while discussing strategic categorizations for AHD.



- Dr. Vichea proposed sharing the findings in a publication format, recommending discussions in smaller groups, focusing specifically on how best to disseminate valuable insights.

## 2. Update on Guidelines Presentation (ACU)

- Emphasized that despite new guidelines, WHO staging or clinical stages should be referenced when CD4 or other testing results are unavailable.
- A form to record WHO staging was discussed, highlighting that updates should be made at each visit, although a lack of data recording was noted.

## 3. TAF Presentation

- Concerns regarding the clarity of objectives related to TAF were noted, with a specific mention of TAF being used in place of TLD for patients with renal failure and who cannot use TLD.
- Requiring further instruction and formal documentation. ACU and LMU are preparing this instruction.
- Updates to HPV screening and TAF usage in alignment with new guidelines.
- Management of TAF stock was discussed, indicating that TLD and TAF expiration dates should be synchronized. Notable, TAF didn't used instead of TLD in general, and the price of TAF was higher than the price of TLD.

## 4. Others

- The meeting convened to discuss the evaluation of the QR code from the Department of Hospital Service (DHS) versus the PSF from the NCHADS. The members expressed uncertainty regarding whether the evaluations were aligned.



QR Code from DHS

## Conclusion and Next Steps

The team agreed that all decisions should be based on solid research and stick closely to the main topics discussed. Moving forward, they'll focus on making CD4 testing a regular part of patient care, improving screening processes, and providing clearer instructions on how to use TAF in treatment.

Seen and Approved by

A blue ink signature of Ouk Vichea, written over a red circular official stamp of NCHADS-SI.

Assist. Prof. Ouk Vichea  
Director of NCHADS-SI

Certified by

A blue ink signature of Dr. Ngauv Bora.

Dr. Ngauv Bora  
Deputy Director of NCHADS  
(Head of AIDS Care Unit)

Prepared by

A blue ink signature of Mr. Srorn Makara.

Mr. Srorn Makara  
AIDS Care Medical Officer